The next big way to make money might be short-selling the stock of a company that you believe to have a security flaw.
It’s certainly what Carson Block, the founder of research firm Muddy Waters, tried to do when he issued a report announcing that he was shorting shares of the medical device manufacturer St. Jude. He claimed that the company’s pacemakers and defibrillators could be easily hacked—perhaps with fatal consequences.
The move was the result of research conducted by a security firm called MedSec Holdings. Block shorted stock in the company based on the assumption that public knowledge of such a vulnerability would cause the St. Jude share price to fall. It did.
It’s actually unclear whether the claims made by MedSec and Block are totally accurate. St. Jude has called them “false and misleading," while University of Michigan medical device security expert Kevin Fu has also questioned their accuracy.
But facts alone do not shape the financial markets.
So markets moved, while financial experts rushed to speak with medical device cybersecurity consultants and find out if the reports were accurate. Jonathan Butts, one such consultant, told Bloomberg that the situation “is almost like The Big Short—someone saw something that nobody else did."
In fact, also much like The Big Short, this kind of trade is “entirely novel,” according to the Bloomberg piece, and it might have some fairly profound ramifications in the future.
Financial markets can shift quickly, and it’s not clear that analysts at banks are particularly well-placed to determine the veracity of these kinds of security claims. Wall Street, then, may potentially look to identify new expertise to help them move faster in such situations.
Hackers may be able to get in on the profits, too. Rather than quietly announcing vulnerabilities online or at conferences, many security experts might be tempted to follow MedSec in sharing their discoveries with traders. It could be worth their while—though it may add insult to injury for the companies that are affected.
This startup wants to copy you into an embryo for organ harvesting
With plans to create realistic synthetic embryos, grown in jars, Renewal Bio is on a journey to the horizon of science and ethics.
VR is as good as psychedelics at helping people reach transcendence
On key metrics, a VR experience elicited a response indistinguishable from subjects who took medium doses of LSD or magic mushrooms.
This artist is dominating AI-generated art. And he’s not happy about it.
Greg Rutkowski is a more popular prompt than Picasso.
This nanoparticle could be the key to a universal covid vaccine
Ending the covid pandemic might well require a vaccine that protects against any new strains. Researchers may have found a strategy that will work.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.